{"id":746024,"date":"2019-06-02T06:30:00","date_gmt":"2019-06-02T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/"},"modified":"2025-05-12T08:58:03","modified_gmt":"2025-05-12T12:58:03","slug":"lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/","title":{"rendered":"LYNPARZA\u00ae (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       22% of Patients Receiving LYNPARZA Remained Progression-Free After        Two Years vs. 10% on Placebo, Following Platinum-Based Chemotherapy     <\/p>\n<p class=\"bwalignc\">       AstraZeneca and Merck\u2019s LYNPARZA is the Only PARP Inhibitor to        Demonstrate Benefit in This Setting in a Phase 3 Trial     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United<br \/>\n      States and Canada, today announced detailed results from the Phase 3<br \/>\n      POLO trial evaluating LYNPARZA tablets as a first-line maintenance<br \/>\n      monotherapy for patients with germline <i>BRCA<\/i>-mutated (g<i>BRCA<\/i>m)<br \/>\n      metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose<br \/>\n      disease had not progressed following platinum-based chemotherapy. The<br \/>\n      results of the trial will be featured today in a press briefing at the 55<sup>th<\/sup><br \/>\n      Annual Meeting of the American Society of Clinical Oncology (ASCO) in<br \/>\n      Chicago and presented as a late-breaker oral presentation at 1:00 p.m.<br \/>\n      CDT during the plenary session (Abstract #LBA4). The results will also<br \/>\n      be published online simultaneously in the <i>New England Journal of<br \/>\n      Medicine<\/i> <i>(NEJM)<\/i>.\n    <\/p>\n<p>\n      Results from the trial showed a statistically-significant and<br \/>\n      clinically-meaningful improvement in progression-free survival (PFS) for<br \/>\n      LYNPARZA compared to placebo, reducing the risk of disease progression<br \/>\n      or death by 47% (HR 0.53 [95% CI 0.35-0.82], p=0.004). The median PFS<br \/>\n      for patients treated with LYNPARZA was 7.4 months compared to 3.8 months<br \/>\n      for those on placebo, with more than twice as many patients remaining<br \/>\n      progression free at both one year (34% on LYNPARZA vs. 15% on placebo)<br \/>\n      and two years (22% vs. 10%) respectively.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td colspan=\"7\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\" colspan=\"7\">\n<p class=\"bwcellpmargin\">\n            <b>Summary of PFS<\/b><br \/>\n<sup>i,ii<\/sup>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\" colspan=\"7\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          Lynparza (n=92)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          Placebo (n=62)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          Number of patients with event (%)<sup>iii<\/sup>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          60 (65)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          44 (71)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          Median (in months)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          7.4\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          3.8\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          Hazard ratio (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"4\">\n          0.53 (0.35-0.82)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          P-value\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"4\">\n          P=0.004\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      <sup>i Blinded, independent central review<\/sup><br \/>\n<br \/>\n<sup>ii Median<br \/>\n      duration of follow-up for progression was 9.1 months (range, 0 to 39.6)<br \/>\n      and 3.8 months (range, 0 to 29.8) in the olaparib and placebo arms,<br \/>\n      respectively<\/sup><br \/>\n<br \/>\n<sup>iii Analysis of the primary endpoint was<br \/>\n      performed at 68% data maturity<\/sup>\n    <\/p>\n<p>\n      Jos\u00e9 Baselga, executive vice president, Oncology R&amp;D, AstraZeneca said,<br \/>\n      \u201cThese remarkable results raise new hope for a patient population that<br \/>\n      has seen little progress over the last 20 years. The POLO trial showed<br \/>\n      that at six months, more than twice as many patients taking LYNPARZA<br \/>\n      were progression free compared to those on placebo. We are now working<br \/>\n      with regulatory authorities to bring LYNPARZA to patients as quickly as<br \/>\n      possible.\u201d\n    <\/p>\n<p>\n      Dr. Roy Baynes, senior vice president and head of global clinical<br \/>\n      development, chief medical officer, Merck Research Laboratories, said,<br \/>\n      \u201cWe are encouraged by the results of the POLO trial which showed a<br \/>\n      considerable reduction in risk of disease progression or death with<br \/>\n      LYNPARZA for germline<i> BRCA<\/i>-mutated metastatic pancreatic cancer<br \/>\n      patients who did not progress on chemotherapy. Currently, less than 3%<br \/>\n      of metastatic pancreatic cancer patients survive more than five years<br \/>\n      after diagnosis. The results of this trial reinforce Merck and<br \/>\n      AstraZeneca\u2019s commitment to develop innovative treatments for cancers<br \/>\n      with few options.\u201d\n    <\/p>\n<p>\n      Dr. Hedy L. Kindler, MD, Co-Principal Investigator of the POLO trial and<br \/>\n      professor of medicine, University of Chicago Medicine, said, \u201cDespite<br \/>\n      efforts to identify therapies, targeted or combination treatments to<br \/>\n      improve patient outcomes, pancreatic cancer remains an area of high<br \/>\n      unmet need. The results of the POLO trial may open the door to a new era<br \/>\n      of personalized, biomarker-led care in metastatic pancreatic cancer and<br \/>\n      reinforces the importance of knowing <i>BRCA <\/i>status at diagnosis.\u201d\n    <\/p>\n<p>\n      The safety and tolerability profile of LYNPARZA in the POLO trial was in<br \/>\n      line with that observed in prior clinical trials. The most common<br \/>\n      adverse events (AEs) \u226520% were fatigue\/asthenia (60%), nausea (45%),<br \/>\n      abdominal pain (29%), diarrhea (29%), anemia (28%), decreased appetite<br \/>\n      (25%) and constipation (23%). The most common \u2265 grade 3 AEs were anemia<br \/>\n      (11%), fatigue\/asthenia (5%), decreased appetite (3%), abdominal pain<br \/>\n      (2%), vomiting (1%) and arthralgia (1%). Around 84% of patients on<br \/>\n      LYNPARZA remained on the recommended starting dose, while 16% had a dose<br \/>\n      reduction vs. 97% who remained on the recommended dose with placebo,<br \/>\n      while 3% had a dose reduction. Additionally, 95% of patients on LYNPARZA<br \/>\n      continued treatment without an AE-related discontinuation, while 5% had<br \/>\n      an AE-related discontinuation vs. 98% who continued treatment without an<br \/>\n      AE-related discontinuation and 2% that had an AE-related discontinuation<br \/>\n      with placebo.\n    <\/p>\n<p>\n      LYNPARZA is not currently approved by the U.S. Food and Drug<br \/>\n      Administration (FDA) for g<i>BRCA<\/i>m pancreatic cancer.\n    <\/p>\n<p>\n      LYNPARZA is currently approved in 64 countries, including those in the<br \/>\n      EU, for the maintenance treatment of platinum-sensitive relapsed ovarian<br \/>\n      cancer regardless of <i>BRCA<\/i> status. It is approved in the U.S. as<br \/>\n      first-line maintenance treatment in <i>BRCA<\/i>m advanced ovarian cancer<br \/>\n      following response to platinum-based chemotherapy. It is also approved<br \/>\n      in 38 countries, including the U.S., countries in the EU, and Japan, for<br \/>\n      germline <i>BRCA<\/i>m HER2-negative metastatic breast cancer previously<br \/>\n      treated with chemotherapy; in the EU this includes locally advanced<br \/>\n      breast cancer. Regulatory reviews are underway in other jurisdictions<br \/>\n      for both ovarian cancer and breast cancer.\n    <\/p>\n<p>\n      <b>About POLO<\/b>\n    <\/p>\n<p>\n      POLO is a Phase 3 randomized, double-blinded, placebo-controlled,<br \/>\n      multi-center study of LYNPARZA tablets (300 mg twice daily) as<br \/>\n      maintenance monotherapy vs. placebo. The trial randomized 154 patients<br \/>\n      with g<i>BRCA<\/i>m metastatic pancreatic cancer whose disease had not<br \/>\n      progressed on first-line platinum-based chemotherapy. Patients were<br \/>\n      randomized (3:2) to receive LYNPARZA or placebo until disease<br \/>\n      progression. The primary endpoint was PFS and key secondary endpoints<br \/>\n      include overall survival, time to second disease progression, overall<br \/>\n      response rate, disease control rate and health-related quality of life.\n    <\/p>\n<p>\n      <b>About Pancreatic Cancer<\/b>\n    <\/p>\n<p>\n      Pancreatic cancer is the 12<sup>th <\/sup>most common cancer worldwide,<br \/>\n      with 458,918 new cases in 2018 alone. With the worst survival rate of<br \/>\n      all the most common cancers, it is the seventh leading cause of cancer<br \/>\n      death, and less than 3% of patients with metastatic disease survive more<br \/>\n      than five years after diagnosis. Early diagnosis of pancreatic cancer is<br \/>\n      difficult, as often there are no symptoms until it is too late. Around<br \/>\n      80% of patients are diagnosed at the metastatic stage.\n    <\/p>\n<p>\n      There are two types of pancreatic cancer. Exocrine tumors, of which the<br \/>\n      most common type is pancreatic ductal adenocarcinoma (PDAC), start in<br \/>\n      the exocrine cells, where enzymes help to digest food. Neuroendocrine<br \/>\n      tumors start in neuroendocrine cells, which produce hormones, such as<br \/>\n      insulin, that control different functions of the body.\n    <\/p>\n<p>\n      <b>About <i>BRCA <\/i>Mutations<\/b>\n    <\/p>\n<p>\n      <i>BRCA<\/i>1 and <i>BRCA<\/i>2 are human genes that produce proteins<br \/>\n      responsible for repairing damaged DNA and play an important role in<br \/>\n      maintaining the genetic stability of cells. When either of these genes<br \/>\n      is mutated, or altered, such that its protein product either is not made<br \/>\n      or does not function correctly, DNA damage may not be repaired properly,<br \/>\n      and cells become unstable. As a result, cells are more likely to develop<br \/>\n      additional genetic alterations that can lead to cancer.\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib)<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a first-in-class PARP inhibitor and the first targeted<br \/>\n      treatment to potentially exploit DNA damage response (DDR) pathway<br \/>\n      deficiencies, such as <i>BRCA<\/i> mutations, to preferentially kill<br \/>\n      cancer cells. Inhibition of PARP with LYNPARZA leads to the trapping of<br \/>\n      PARP bound to DNA single-strand breaks, stalling of replication forks,<br \/>\n      their collapse and the generation of DNA double-strand breaks and cancer<br \/>\n      cell death. LYNPARZA is being tested in a range of tumor types with<br \/>\n      defects and dependencies in the DDR.\n    <\/p>\n<p>\n      LYNPARZA, which is being jointly developed and commercialized by<br \/>\n      AstraZeneca and Merck, has a broad and advanced clinical trial<br \/>\n      development program, and AstraZeneca and Merck are working together to<br \/>\n      understand how it may affect multiple PARP-dependent tumors as a<br \/>\n      monotherapy and in combination across multiple cancer types.\n    <\/p>\n<p>\n      <b>IMPORTANT SAFETY INFORMATION<\/b>\n    <\/p>\n<p>\n      <b>CONTRAINDICATIONS<\/b>\n    <\/p>\n<p>\n      There are no contraindications for LYNPARZA.\n    <\/p>\n<p>\n      <b>WARNINGS AND PRECAUTIONS<\/b>\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML): <\/b>Occurred<br \/>\n      in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the majority<br \/>\n      of events had a fatal outcome. The duration of therapy in patients who<br \/>\n      developed secondary MDS\/AML varied from &lt;6 months to &gt;2 years. All of<br \/>\n      these patients had previous chemotherapy with platinum agents and\/or<br \/>\n      other DNA-damaging agents, including radiotherapy, and some also had a<br \/>\n      history of more than one primary malignancy or of bone marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood count for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA and monitor blood count<br \/>\n      weekly until recovery.\n    <\/p>\n<p>\n      If the levels have not recovered to Grade 1 or less after 4 weeks, refer<br \/>\n      the patient to a hematologist for further investigations, including bone<br \/>\n      marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA<br \/>\n      if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis: <\/b>Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt LYNPARZA treatment and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity: <\/b>Based on its mechanism of action and<br \/>\n      findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is<br \/>\n      recommended for females of reproductive potential prior to initiating<br \/>\n      treatment.\n    <\/p>\n<p>\n      <i>Females<\/i>\n    <\/p>\n<p>\n      Advise females of reproductive potential of the potential risk to a<br \/>\n      fetus and to use effective contraception during treatment and for 6<br \/>\n      months following the last dose.\n    <\/p>\n<p>\n      <i>Males<\/i>\n    <\/p>\n<p>\n      Advise male patients with female partners of reproductive potential or<br \/>\n      who are pregnant to use effective contraception during treatment and for<br \/>\n      3 months following the last dose of LYNPARZA and to not donate sperm<br \/>\n      during this time.\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014First-Line Maintenance <i>BRCA<\/i>m Advanced<br \/>\n      Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226510% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>first-line maintenance setting<\/b><br \/>\n      for <b>SOLO-1 <\/b>were: nausea (77%), fatigue (67%), abdominal pain<br \/>\n      (45%), vomiting (40%), anemia (38%), diarrhea (37%), constipation (28%),<br \/>\n      upper respiratory tract infection\/influenza\/ nasopharyngitis\/bronchitis<br \/>\n      (28%), dysgeusia (26%), decreased appetite (20%), dizziness (20%),<br \/>\n      neutropenia (17%), dyspepsia (17%), dyspnea (15%), leukopenia (13%), UTI<br \/>\n      (13%), thrombocytopenia (11%), and stomatitis (11%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>first-line maintenance setting for<br \/>\n      SOLO-1<\/b> were: decrease in hemoglobin (87%), increase in mean<br \/>\n      corpuscular volume (87%), decrease in leukocytes (70%), decrease in<br \/>\n      lymphocytes (67%), decrease in absolute neutrophil count (51%), decrease<br \/>\n      in platelets (35%), and increase in serum creatinine (34%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Maintenance Recurrent Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting <\/b>for <b>SOLO-2<\/b><br \/>\n      were: nausea (76%), fatigue (including asthenia) (66%), anemia (44%),<br \/>\n      vomiting (37%), nasopharyngitis\/upper respiratory tract infection<br \/>\n      (URI)\/influenza (36%), diarrhea (33%), arthralgia\/myalgia (30%),<br \/>\n      dysgeusia (27%), headache (26%), decreased appetite (22%), and<br \/>\n      stomatitis (20%).\n    <\/p>\n<p>\n      <b>Study 19: <\/b>nausea (71%), fatigue (including asthenia) (63%),<br \/>\n      vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract<br \/>\n      infection (22%), constipation (22%), headache (21%), decreased appetite<br \/>\n      (21%), and dyspepsia (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting (SOLO-2\/Study<br \/>\n      19<\/b>) were: increase in mean corpuscular volume (89%\/82%), decrease in<br \/>\n      hemoglobin (83%\/82%), decrease in leukocytes (69%\/58%), decrease in<br \/>\n      lymphocytes (67%\/52%), decrease in absolute neutrophil count (51%\/47%),<br \/>\n      increase in serum creatinine (44%\/45%), and decrease in platelets<br \/>\n      (42%\/36%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Advanced g<i>BRCA<\/i>m ovarian cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer<br \/>\n      after 3 or more lines of chemotherapy <\/b>(pooled from 6 studies) were:<br \/>\n      fatigue\/asthenia (66%), nausea (64%), vomiting (43%), anemia (34%),<br \/>\n      diarrhea (31%), nasopharyngitis\/upper respiratory tract infection (URI)<br \/>\n      (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%), and<br \/>\n      arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer <\/b>(pooled<br \/>\n      from 6 studies) were: decrease in hemoglobin (90%), mean corpuscular<br \/>\n      volume elevation (57%), decrease in lymphocytes (56%), increase in serum<br \/>\n      creatinine (30%), decrease in platelets (30%), and decrease in absolute<br \/>\n      neutrophil count (25%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014g<i>BRCA<\/i>m, HER2-negative metastatic breast<br \/>\n      cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in <b>OlympiAD<\/b><br \/>\n      were: nausea (58%), anemia (40%), fatigue (including asthenia) (37%),<br \/>\n      vomiting (30%), neutropenia (27%), respiratory tract infection (27%),<br \/>\n      leukopenia (25%), diarrhea (21%), and headache (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in <b>OlympiAD<br \/>\n      <\/b>were: decrease in hemoglobin (82%), decrease in lymphocytes (73%),<br \/>\n      decrease in leukocytes (71%), increase in mean corpuscular volume (71%),<br \/>\n      decrease in absolute neutrophil count (46%), and decrease in platelets<br \/>\n      (33%).\n    <\/p>\n<p>\n      <b>DRUG INTERACTIONS<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents: <\/b>Clinical studies of LYNPARZA in combination<br \/>\n      with other myelosuppressive anticancer agents, including DNA-damaging<br \/>\n      agents, indicate a potentiation and prolongation of myelosuppressive<br \/>\n      toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors: <\/b>Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be<br \/>\n      co-administered, reduce the dose of LYNPARZA. Advise patients to avoid<br \/>\n      grapefruit, grapefruit juice, Seville oranges, and Seville orange juice<br \/>\n      during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers: <\/b>Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA. If a moderate inducer cannot be avoided,<br \/>\n      there is a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>USE IN SPECIFIC POPULATIONS<\/b>\n    <\/p>\n<p>\n      <b>Lactation: <\/b>No data are available regarding the presence of<br \/>\n      olaparib in human milk, its effects on the breastfed infant or on milk<br \/>\n      production. Because of the potential for serious adverse reactions in<br \/>\n      the breastfed infant, advise a lactating woman not to breastfeed during<br \/>\n      treatment with LYNPARZA and for 1 month after receiving the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use: <\/b>The safety and efficacy of LYNPARZA have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Hepatic Impairment: <\/b>No adjustment to the starting dose is<br \/>\n      required in patients with mild or moderate hepatic impairment<br \/>\n      (Child-Pugh classification A and B). There are no data in patients with<br \/>\n      severe hepatic impairment (Child-Pugh classification C).\n    <\/p>\n<p>\n      <b>Renal Impairment: <\/b>No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment (CLcr=51-80 mL\/min) but patients<br \/>\n      should be monitored closely for toxicity. In patients with moderate<br \/>\n      renal impairment (CLcr=31-50 mL\/min), reduce the dose to 200 mg twice<br \/>\n      daily. There are no data in patients with severe renal impairment or<br \/>\n      end-stage renal disease (CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>INDICATIONS<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n    <\/p>\n<p>\n      <b>First-Line Maintenance <i>BRCA<\/i>m Advanced Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with deleterious or<br \/>\n      suspected deleterious germline or somatic <i>BRCA<\/i>-mutated (g<i>BRCA<\/i>m<i><br \/>\n      <\/i>or s<i>BRCA<\/i>m) advanced epithelial ovarian, fallopian tube or<br \/>\n      primary peritoneal cancer who are in complete or partial response to<br \/>\n      first-line platinum-based chemotherapy. Select patients with g<i>BRCA<\/i>m<br \/>\n      advanced epithelial ovarian, fallopian tube or primary peritoneal cancer<br \/>\n      for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Maintenance Recurrent Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with recurrent<br \/>\n      epithelial ovarian, fallopian tube, or primary peritoneal cancer, who<br \/>\n      are in complete or partial response to platinum-based chemotherapy.\n    <\/p>\n<p>\n      <b>Advanced g<i>BRCA<\/i>m ovarian cancer<\/b>\n    <\/p>\n<p>\n      For the treatment of adult patients with deleterious or suspected<br \/>\n      deleterious germline <i>BRCA-<\/i>mutated (g<i>BRCA<\/i>m) advanced<br \/>\n      ovarian cancer who have been treated with 3 or more prior lines of<br \/>\n      chemotherapy. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>g<i>BRCA<\/i>m, HER2-negative metastatic breast cancer<\/b>\n    <\/p>\n<p>\n      In patients with deleterious or suspected deleterious g<i>BRCA<\/i>m<i>, <\/i>human<br \/>\n      epidermal growth factor receptor 2 (HER2)-negative metastatic breast<br \/>\n      cancer who have been treated with chemotherapy in the neoadjuvant,<br \/>\n      adjuvant or metastatic setting. Patients with hormone receptor<br \/>\n      (HR)-positive breast cancer should have been treated with a prior<br \/>\n      endocrine therapy or be considered inappropriate for endocrine therapy.<br \/>\n      Select patients for therapy based on an FDA-approved companion<br \/>\n      diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Please <\/b><br \/>\n<a href=\"https:\/\/www.azpicentral.com\/lynparza_tb\/lynparza_tb.pdf\" rel=\"nofollow\"><br \/>\n<b>click<br \/>\n      here for complete Prescribing Information, including Patient Information<br \/>\n      (Medication Guide)<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      In July 2017, AstraZeneca and Merck, known as MSD outside the United<br \/>\n      States and Canada, announced a global strategic oncology collaboration<br \/>\n      to co-develop and co-commercialize LYNPARZA, the world\u2019s first PARP<br \/>\n      inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for<br \/>\n      multiple cancer types. Working together, the companies will develop<br \/>\n      LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as monotherapies. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment. As<br \/>\n      part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers. For more information about our oncology clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/index.html\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/www.youtube.com\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2018 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media Contacts:<br \/>Pamela Eisele<br \/>(267) 305-3558     <\/p>\n<p>       Michael Close<br \/>(267) 305-1211     <\/p>\n<p>       Investor Contacts:<br \/>Teri Loxam<br \/>(908) 740-1986     <\/p>\n<p>       Michael DeCarbo<br \/>(908) 740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced detailed results from the Phase 3 POLO trial evaluating LYNPARZA tablets as a first-line maintenance monotherapy for patients with germline BRCA -mutated (g BRCA m) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose disease had not progressed following platinum-based chemotherapy. The results of the trial will be featured today in a press briefing at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago and presented as a late-breaker oral presentation at 1:00 p.m. CDT during the plenary session (Abstract #LBA4). The results will also be published online simultaneously in the New England Journal of Medicine (NEJM) . Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for LYNPARZA compared to placebo, reducing the risk of disease progression or death by 47%<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,289,56],"class_list":["post-746024","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LYNPARZA\u00ae (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LYNPARZA\u00ae (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced detailed results from the Phase 3 POLO trial evaluating LYNPARZA tablets as a first-line maintenance monotherapy for patients with germline BRCA -mutated (g BRCA m) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose disease had not progressed following platinum-based chemotherapy. The results of the trial will be featured today in a press briefing at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago and presented as a late-breaker oral presentation at 1:00 p.m. CDT during the plenary session (Abstract #LBA4). The results will also be published online simultaneously in the New England Journal of Medicine (NEJM) . Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for LYNPARZA compared to placebo, reducing the risk of disease progression or death by 47%\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:58:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\\\/\",\"name\":\"LYNPARZA\u00ae (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-06-02T06:30:00+00:00\",\"dateModified\":\"2025-05-12T12:58:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LYNPARZA\u00ae (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LYNPARZA\u00ae (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/","og_locale":"en_US","og_type":"article","og_title":"LYNPARZA\u00ae (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer - Merck.com","og_description":"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced detailed results from the Phase 3 POLO trial evaluating LYNPARZA tablets as a first-line maintenance monotherapy for patients with germline BRCA -mutated (g BRCA m) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose disease had not progressed following platinum-based chemotherapy. The results of the trial will be featured today in a press briefing at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago and presented as a late-breaker oral presentation at 1:00 p.m. CDT during the plenary session (Abstract #LBA4). The results will also be published online simultaneously in the New England Journal of Medicine (NEJM) . Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for LYNPARZA compared to placebo, reducing the risk of disease progression or death by 47%","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:58:03+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/","name":"LYNPARZA\u00ae (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-06-02T06:30:00+00:00","dateModified":"2025-05-12T12:58:03+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"LYNPARZA\u00ae (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"443c27fe-7240-446c-973b-cb6bda9f2c26","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2019\/06\/1\/POLO_KM_Curve.jpg","size":"60583","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2019\/06\/1\/merck_logo.jpg","size":"21167","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/LYNPARZA-olaparib-First-Line-Maintenance-Therapy-Nearly-Doubled-the-Time-Without-Disease-Progression-or-Death-in-Phase-3-POLO-Trial-f-MNK83.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746024\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746024"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}